Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment (Q37982112)

26 August 2017

title

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

André J Scheen

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

383-394

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin: effects on micro and macrovascular complications in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin effects revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin + saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

The unrecognized prevalence of chronic kidney disease in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Medications in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Lactic acidosis induced by metformin: incidence, management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Review: metformin: potential benefits and use in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Kidney function and age are both predictors of pharmacokinetics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Current understanding of the pharmacogenomics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Reduction of metformin renal tubular secretion by cimetidine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

A risk-benefit assessment of metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin use in renal dysfunction: is a serum creatinine threshold appropriate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Limitations of metformin use in patients with kidney disease: are they warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Renal status among patients using metformin in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

The cardioprotective effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Metformin: effective and safe in renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658771

10.1517/17425255.2012.658771

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference